CHA Biotech
Financials
Valuation Metrics
CHA Biotech's Market Cap is ₩7326B. At end of 2025 it was ₩1.4T. Ranked #370 of 2,421 in KR market (top 15%), #119 of 1,640 on KOSDAQ (top 7%), #9 of 96 in Health Care Equipment & Services (top 9%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 732.63B KRW | KR#370/2,421 Sec#9/96 |
| Revenue | 1.31T KRW | KR#346/2,421 Sec#2/96 |
| Net Income | -16.43B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 2.86T KRW | KR#248/2,421 Sec#2/96 |
| Net Assets | 1.03T KRW | KR#290/2,421 Sec#3/96 |
| Employees | 334 | KR#720/2,421 Sec#19/96 |
| Value | ||
| P/B | 0.71x | KR#1,149/2,421 Sec#24/96 |
| P/S | 0.56x | KR#996/2,421 Sec#12/96 |
| FCF Yield | -29.96% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -1.60% | KR#1,661/2,421 Sec#56/96 |
| ROA | -0.57% | KR#1,625/2,421 Sec#53/96 |
| Op. Margin | -5.68% | KR#1,878/2,421 Sec#59/96 |
| Revenue Growth | 13.93% | KR#724/2,421 Sec#39/96 |
| Financial Health | ||
| Debt Ratio | 178.44% | KR#2,032/2,421 Sec#88/96 |
| Total Debt | 1.29T KRW | KR#174/2,421 Sec#1/96 |
| FCF | -219.51B KRW | KR#2,175/2,421 Sec#86/96 |
| Cash | 303.36B KRW | KR#193/2,421 Sec#1/96 |
| Current Ratio | 0.89x | KR#1,852/2,421 Sec#84/96 |
| Dividend | ||
| Div. Yield | 0.11% | KR#1,365/2,421 Sec#39/96 |
| Div. Growth | -67.82% | KR—/2,421 Sec—/96 |
| Performance | ||
| 1Y Return | -29.33% | KR#1,544/2,421 Sec#40/96 |
| 1M Return | -7.29% | KR#1,951/2,421 Sec#67/96 |
| From 52W High | -67.10% | KR#2,118/2,421 Sec#76/96 |
| 1Y MDD | -67.55% | KR#1,867/2,421 Sec#65/96 |
| Trading | ||
| Volume | 277,823 shares | KR#381/2,421 Sec#13/96 |
| Trading Value | 2.17B KRW | KR#541/2,421 Sec#10/96 |
| Foreign Own. | 7.88% | KR#563/2,421 Sec#16/96 |
| Per Share | ||
| EPS | -177 KRW | KR—/2,421 Sec—/96 |
| BPS | 11,044 KRW | KR#925/2,421 Sec#18/96 |
Company Info
CHA Biotech, established in 2002, engages in umbilical cord blood banking, stem cell research and cell therapy development, and anti-aging services. Through its major subsidiaries, the company operates pharmaceutical, global CDMO, and global medical network businesses, leveraging an ecosystem-based clinical and new drug development platform. Revenue generation is expected from advanced regenerative medicine treatment sales and global out-licensing. It is also strengthening its global network by establishing the world's largest Cell and Gene Therapy (CGT) manufacturing facility. CHA Biotech is headquartered in Gangnam-gu, Seoul.